anemia
FDA Approves Jesduvroq, First Oral Treatment for Anemia Related to Dialysis
More than 500,000 U.S. adults require dialysis, a treatment that filters the blood and removes excess fluid from ...
FEBRUARY 3, 2023
FDA Approves PK Activator to Treat Hemolytic Anemia
he FDA approved mitapivat to treat hemolytic anemia in adults with pyruvate kinase (PK) deficiency, a rare genetic ...
FEBRUARY 18, 2022
FDA Approves Enjaymo for Adults With Rare Type of Anemia
Sutimlimab-jome infusions decrease the need for red blood cell transfusion due to hemolysis in adults with cold ...
FEBRUARY 4, 2022
FDA Approves Reblozyl to Treat Anemia in Some Patients With MDS
The FDA approved luspatercept-aamt (Reblozyl, Celgene) for the treatment of anemia in adults with very low- to ...
APRIL 10, 2020
First Epoetin alfa Biosimilar Receives FDA Approval for Anemia
Retacrit is the first U.S. biosimilar erythropoiesis-stimulating agent (ESA). Although not listed as an ...
MAY 15, 2018
FDA Advisory Committee Recommends Approval for New Biosimilar of Epogen/Procrit
ODAC has recommended that Pfizer’s epoetin alfa biosimilar be approved across all indications. This marks the ...
MAY 26, 2017
